Hepatology · 2021 · 356 citations · 28 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyHepatic PharmacotherapyMetabolic RegulationDiabetes MellitusInsulin ResistanceHepatic Insulin ResistanceImpaired Insulin SensitivityInsulin Sensitivity IndicesPeroxisome Proliferator Receptor SignalingPeroxisome Proliferator-activated Receptor SignalingPeroxisome Proliferator-activated ReceptorsPrimary Efficacy EndpointsSerum Alanine Aminotransferase
BACKGROUND AND AIMS: NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves insulin sensitivity, and lipid and glycemic parameters. Saroglitazar improved NASH histology in animal studies. In this randomized controlled clinical trial, we evaluated the efficacy and safety of saroglitazar in patients with NAFLD/NASH. APPROACH AND RESULTS: were randomized in a 1:1:1:1 ratio to receive placebo or saroglitazar 1 mg, 2 mg, or 4 mg for 16 weeks. The primary efficacy endpoint was percentage change from baseline in ALT levels at week 16. Liver fat content (LFC) was assessed by MRI proton density fat fraction. The least-squares mean percent change from baseline in ALT at week 16 was -25.5% (5.8), -27.7% (5.9), and -45.8% (5.7), with saroglitazar 1 mg, 2 mg, and 4 mg, respectively, versus 3.4% (5.6) in placebo (P < 0.001 for all). Compared with placebo, saroglitazar 4 mg improved LFC (4.1% [5.9] vs. -19.7% [5.6]), adiponectin (-0.3 μg/mL [0.3] vs. 1.3 μg/mL [0.3]), homeostatic model assessment-insulin resistance (-1.3 [1.8] vs. -6.3 [1.7]), and triglycerides (-5.3 mg/dL [10.7] vs. -68.7 mg/dL [10.3]) (P < 0.05 for all). Saroglitazar 4 mg also improved lipoprotein particle composition and size and reduced lipotoxic lipid species. Saroglitazar was well-tolerated. A mean weight gain of 1.5 kg was observed with saroglitazar 4 mg versus 0.3 kg with placebo (P = 0.27). CONCLUSIONS: Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier: NCT03061721.).
28
Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆
Christi A Matteoni, Zobair M. Younossi, T GRAMLICH et al. · Gastroenterology · 1999 · 3.4K citations · Full text
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley et al. · New England Journal of Medicine · 2010 · 3.3K citations · Full text
Nonalcoholic Fatty Liver Disease
Giulio Marchesini, Mara Brizi, Giampaolo Bianchi et al. · Diabetes · 2001 · 2.6K citations · Full text
Medicine, Pathology, Hepatology +11